Nutrien Ltd (NTR) Stock Price Today
Aura AI Summary
Key Stats
- $33.41BMarket Cap
- -Volume
- Basic MaterialsSector
- $83.9452W High
- $53.6452W Low
- -Typical Hold Time
- $45.22BEnterprise Value
- 3.12%Div Yield
- -Trading Activity
Track Nutrien Ltd (NTR) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Nutrien Ltd has traded between a low of $53.64 and a high of $83.94, highlighting its annual price range. Buy and sell Nutrien Ltd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Most Recent News
Scotiabank raises Simon Property Group price target to $222 after strong Q2 results and higher full-year guidance.
Scotiabank raised its price target for Simon Property Group to $222 from $220 while maintaining a neutral Sector Perform rating. The real estate trust reported a 19.5% revenue increase to $1.79 billion in Q2 2026, with stable 96% occupancy at its U.S...

UiPath CEO Daniel Dines sells 1.4M shares for $22.5M
UiPath CEO Daniel Dines has sold 1.4 million shares of the company, raising $22.5 million. This move may indicate a personal liquidity event or portfolio rebalancing by the CEO. Investors might watch for any impact on the stock price or future inside...

Hims & Hers faces federal lawsuit and price target cut amid legal scrutiny over billing and data practices
Hims & Hers Health is under federal investigation and lawsuit for alleged deceptive billing, difficult subscription cancellations, and unauthorized sharing of health data with advertisers. Barclays lowered its price target from $39 to $35, reflecting...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.